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Editorial

Break Out: Urogenital Schistosomiasis and Schistosoma
haematobium Infection in the Post-Genomic Era
Paul J. Brindley1*, Peter J. Hotez2,3*
1 Department of Microbiology, Immunology, and Tropical Medicine, George Washington University School of Medicine and Health Sciences, Washington DC, United
States of America, 2 Departments of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine at Baylor College of Medicine, Houston,
Texas, United States of America, 3 Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development, Houston, Texas, United States of America

The newly completed whole genome sequence of
Schistosoma haematobium, the leading cause
of human schistosomiasis and an emerging cofactor in Africa’s AIDS and cancer epidemics,
together with rapidly advancing genetic manipulation technologies, is providing new insights that
could lead to the development of a new generation
of tools for eliminating this ancient scourge.
Today, more than 90% of the roughly
200 million cases of schistosomiasis occur
in Africa [1,2], of which approximately
two-thirds are caused by Schistosoma haematobium [3], the etiologic agent of urogenital
schistosomiasis. More recently, Charles
King and his colleagues have suggested
that the number of cases of S. haematobium
may be much greater than previously
believed, even possibly double or triple
that of earlier prevalence estimates [4]. If
confirmed, urogenital schistosomiasis may
represent the most common infection or
even adverse health condition in subSaharan Africa.
Urogenital schistosomiasis results when
adult female S. haematobium worm pairs
living in the veins draining key pelvic
organs, including the bladder, uterus, and
cervix, release terminal-spine eggs that
penetrate the tissues and are excreted in in
the urine to allow propagation of the
parasite life cycle. However, many schistosome eggs fail to exit the body, and
come to embolize within the capillary beds
of pelvic end-organs, especially the tissues
of the bladder, ureters, and female and
male genital organs. Here they induce
granulomas and ultimately small fibrotic
nodules known as ‘‘sandy patches’’ [5].
Numerous granulomas and sandy patches
cause bladder and ureteral inflammation
associated with hematuria in more than
50% of the cases [3], in addition to organ
deformities associated with ureteric obstruction, secondary urinary tract and
renal infections, hydronephrosis, and ultimately renal failure in millions of people
living in Africa [5].
Up to 75% of girls and women with
chronic S. haematobium infection will also
experience deposition of eggs with granulomas and sandy patches on their uterus,
cervix, and lower genital tract [6,7]. The

resulting female genital schistosomiasis
(FGS) is associated with contact bleeding,
discharge, pain on intercourse, and secondary infections and diminished fertility;
it is also a source of shame and stigma
[6,7]. FGS is not a rare condition—one
estimate suggested that of the estimated 70
million children currently infected with S.
haematobium, approximately 19 million girls
and women will eventually develop FGS
in the coming decade [8]. However, these
numbers are likely conservative estimates,
such that FGS may represent one of the
most common gynecological conditions in
Africa.
In addition to the pathologies outlined
above, the effects of chronic S. haematobium
infection in children have been linked to
chronic inflammation and pain, as well as
growth stunting and cognitive deficits
among tens of millions of children [4].
FGS has also been identified as a co-factor
in Africa’s AIDS epidemic, especially in
Zimbabwe and Tanzania, where it was
linked to a 3–4 times increased risk in
acquiring HIV infection [6–8]. S. haematobium eggs have now been further identified
as a Group 1 carcinogen responsible for a
unique squamous cell carcinoma, which is
widespread in S. haematobium–endemic
areas [5,9]. S. haematobium also exerts
important host endocrine effects based in
part on its ability to synthesize and release
estradiol [9]. A full consideration of these

and other chronic morbidities that use
disability-adjusted life years (DALYs) as a
metric suggests that chronic urogenital
schistosomiasis may equal or even exceed
malaria or other better-known conditions
in terms of its disease burden in Africa [4].
Despite its overwhelming public health
importance and its well-established links to
HIV/AIDS and cancer, S. haematobium has
been labeled ‘‘the neglected schistosome’’
[10,11]. Indeed, as shown in Table 1, a
search of the literature named in PubMed
(the online database of the US National
Library of Medicine) supports this assertion. Over the last five years, there have
been 644 papers listed in PubMed per
million cases of Asian schistosomiasis
caused by Schistosoma japonicum and 25
papers per million cases of S. mansoni
infection, Africa’s other major schistosome. In contrast, only three papers per
million cases of S. haematobium infection
have appeared in PubMed over the last
five years. (The 342 publications over the
past five years investigating S. haematobium
and schistosomiasis haematobia represent
challenging research; and much effort
went into studies on this organism during
the several decades before that. Much of
this work was undertaken with humans as
the host, compounding the challenges for
the research and encumbering progress.
Although a review of this literature is
beyond the aim of our editorial, studies

Citation: Brindley PJ, Hotez PJ (2013) Break Out: Urogenital Schistosomiasis and Schistosoma haematobium
Infection in the Post-Genomic Era. PLoS Negl Trop Dis 7(3): e1961. doi:10.1371/journal.pntd.0001961
Published March 28, 2013
Copyright: ß 2013 Hotez, Brindley. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: No specific funding was received for this work.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: pbrindley@email.gwu.edu (PJB); hotez@bcm.edu (PJH)
Paul J. Brindley, PhD, is a Deputy Editor of PLOS Neglected Tropical Diseases. He is a professor in the Department
of Microbiology, Immunology and Tropical Medicine, School of Medicine & Health Sciences, The George
Washington University, Washington, DC. He is also the Scientific Director of the Research Center for Neglected
Diseases of Poverty at George Washington University. Peter J. Hotez, MD, PhD, is Co-Editor-in-Chief of PLOS
Neglected Tropical Diseases. He is President of the Sabin Vaccine Institute, Professor and Head of the Section of
Pediatric Tropical Medicine in the Department of Pediatrics at Texas Children’s Hospital and Baylor College of
Medicine, and Dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston,
Texas, United States of America.

PLOS Neglected Tropical Diseases | www.plosntds.org

1

March 2013 | Volume 7 | Issue 3 | e1961

Table 1. Number of citations in PubMed over the last five years, 2008–2012.

Parasite Species

Approximate Number of
Human Cases

Number of PubMed
Citations over the Last
Five Yearsb

PubMed Citations per
Millions of Human Cases

References

Schistosoma japonicum

1 million

644

644

Steinmann et al. 2006 [1]

Schistosoma mansoni

54 milliona

1,371

25

Van der Werf et al. 2003 [3]

Schistosoma haematobium

112 milliona

342

3

Van der Werf et al. 2003 [3]

a

Sub-Saharan Africa only.
Search conducted on July 14, 2012.
doi:10.1371/journal.pntd.0001961.t001
b

such as those by Agnew, Cheever, and
Doenhoff on rodent models of infection
[12,13]; Capron and co-workers on vaccines [14]; Feldmeier, Kjetland, Shiff, and
others on female genital schistosomiasis
and bladder cancer [7,9,15]; Brooker,
Deelder, Hamburger, Mutapi, Sturrock,
and others on epidemiology, co-infections,
and diagnostics [3,16–18]; and Kitron,
Loker, and Rollinson on intermediate host
snails, ecology, and evolutionary aspects
[10,19,20] have provided crucial scaffolds,
the ‘‘shoulders of giants’’ as it were.
Investigators accessing the newly available
genetic tools can now gaze from these
shoulders and hopefully move rapidly to
new interventions for S. haematobium infection. [We apologize to investigators we did
not have space to mention.])
Nonetheless, the field of S. haematobium
research, in contrast to studies for the
other schistosomes, has largely remained
‘‘on the outside looking in’’ with respect to
breakthroughs in the areas of omics, high
throughput drug screening, reverse vaccinology, molecular imaging, bioengineering, structural biology, and molecular
immunology. Whereas some of the dearth
in scientific activity and productivity for
urogenital schistosomiasis can be ascribed
to the fact simply that it is a neglected
tropical disease, this observation cannot
explain why research on S. japonicum and
Schistosoma mansoni has been more active
and fruitful. It is plausible that the
following factors are responsible for this
situation: 1) the absence of mouse animal
models; 2) the absence of in vitro systems;
and 3) the absence of a completed genome
projects and related omics projects.
The good news is that studies conducted
within the past two years suggest that
many of these barriers have now been
surmounted either completely or partially
and that there is a path forward to
facilitate a new era of S. haematobium
research.
1. Animal models of infection. The availability
of mouse models for S. mansoni and S.

japonicum infections has stimulated at
least two generations of molecular and
cellular immunologists to undertake
groundbreaking studies on these two
helminthiases and to unravel the complexities of schistosome-mediated immunopathogenesis [21–23]. Within the
last two years (2011–2012), key studies
have been conducted in genetically
modified knock-out mice to also identify co-factors, leading to improved
understanding of S. haematobium carcinogenesis [24], while microinjection of
S. haematobium eggs in the bladder of
mice has been shown to reproduce
urinary tract fibrosis and other bladder
histopathologic changes typically found
in human urogenital schistosomiasis
[25]. Expansion of such studies, including work in humanized mouse
models, will undoubtedly produce
new insights into parasite-induced immunopathogenesis, carcinogenesis,
FGS, and HIV/AIDS co-infections.
2. In vitro systems. The first report of the
genetic manipulation of S. haematobium
by short interfering ribonucleic acids
(siRNAs) into parasite eggs, and subsequent culturing of eggs, miracidia,
schistosomula, and adult schistosomes
[11], portend enormous promise for
analyzing novel S. haematobium genes.
Such in vitro studies would complement ongoing in vivo projects in mice
as outlined above. Simultaneously,
work in mammalian cell lines and
transgenic schistosomes will provide
additional insights into parasite-mediated carcinogenesis [26,27].
3. Omics. In 2012, the 385-Mb genome of
S. haematobium was completed at 74-fold
coverage [28–30]. While there was a
high synteny between the roughly
13,000 genes of S. haematobium and the
other two schistosomes, a number of
unique S. haematobium genes were
identified, including genes encoding
novel drug targets, estrogen-synthesizing enzymes that might be involved in
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neocarcinogenesis of eggs in situ, and
molecules with immunomodulatory
functions.
It is particularly promising and of great
importance that the development of
mouse models for S. haematobium infections
is maturing roughly in parallel with the
development of in vitro technologies for
parasite gene manipulation together with
the completion of whole genome sequencing for S. haematobium. Assuming additional
proteomic and metabolomics projects for
S. haematobium move forward, together with
epigenetic studies and advances with in
vitro methods linked to RNAi and transgenesis, the next few years could become a
watershed for S. haematobium research. In
so doing, we can anticipate striking new
insights into parasite-induced carcinogenesis and HIV/AIDS co-infections that
result from urogenital schistosomiasis.
Breakthroughs in S. haematobium studies
will require international cooperation and
a new level of support. The community of
S. haematobium researchers is not numerically large, but could easily embrace
scientists working on other schistosomes
as well as those involved in cancer and
AIDS research. One way to proceed is to
establish a consortium of S. haematobium
investigators and projects, possibly
through joint funding from the US
National Cancer Institute, National Institute of Allergy and Infectious Disease
(NIAID) and/or other institutes or centers
of the National Institutes of Health (NIH),
the Wellcome Trust, European Union and
government support, and possibly private
donors such as the Bill & Melinda Gates
Foundation. We believe that no one
agency will likely do it all in terms of
significantly advancing the S. haematobium
research and development agenda. We
also note that, with taxpayer-funded
support from the NIAID-NIH, an Egyptian strain of S. haematobium and its
intermediate host snail Bulinus truncatus
reagents are available to interested investigators anywhere in the world from the
March 2013 | Volume 7 | Issue 3 | e1961

BEI Resources catalog of the American
Type Culture Collection [31].
In 2012, the global community responded to the call that ‘‘Africa is desperate for
praziquantel’’ [32], with an unprecedented commitment of praziquantel donations
from Merck KgaA and a London Declaration as a first step for the elimination of
schistosomiasis as a public health problem

[33]. While the drug donations and a
subsequent 26 May 2012 World Health
Assembly resolution calling for schistosomiasis elimination [34] are essential, we
feel that alone such measures will not
address Africa’s burden of S. haematobium–
induced cancer nor the stealth role of S.
haematobium in promoting Africa’s AIDS
epidemic. In parallel, there needs to be put

in place an aggressive program of research
and development that includes fundamental studies and translational approaches
toward development of new diagnostics,
drugs, and vaccines. Basic research conducted within the last two years has now
set the stage to go that extra mile.
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